Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel

Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I. Marks, Giovanni Martinelli, Oliver Ottmann, Anita Rijneveld, Philippe Rousselot, Josep Ribera, Renato Bassan

Blood (2024) 143 (19): 1891–1902.

https://doi.org/10.1182/blood.2023020794

Published: 2024

Includes: Supplemental data

Journal Articles

Management of ALL in adults: 2024 ELN recommendations from a European expert panel

Blood (2024) 143 (19): 1903–1930.

https://doi.org/10.1182/blood.2023023568

Published: 2024

Includes: Supplemental data

Journal Articles

Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency

Blood (2018) 131 (8): 917–931.

https://doi.org/10.1182/blood-2017-09-807487

Published: 2018

Journal Articles

Delays in Start of Intensification Therapy Are Common for Adults with Acute Lymphoblastic Leukemia, and Are Associated with Decreased Survival in Patients Who Undergo Allogeneic Stem Cell Transplant (SCT)

Anita J. Kumar, MDMS, Phyllis A. Gimotty, PhD, Joel Gelfand, MDMS, Georgina Buck, Jacob M. Rowe, MD, Anthony H Goldstone, MD, Adele Fielding, MB BS, PhD, David I Marks, Mark Litzow, Elisabeth Paietta, PhD, Hillard M. Lazarus, Martin S. Tallman, MD, Selina M. Luger, MD, Alison W. Loren, MDMS

Blood (2014) 124 (21): 208.

https://doi.org/10.1182/blood.V124.21.208.208

Published: 2014

Journal Articles

Barriers To Clinical Trial Enrolment For Teenagers and Young Adults With Acute Lymphoblastic Leukaemia: The Impact of Age Eligibility Criteria

Lorna Anne Fern, BSc, MSc, PhD, Clare Rowntree, PhD, Rachael E Hough, MD, Ajay J Vora, Adele Fielding, MB BS, PhD, Chris Mitchell, Nicholas Goulden, Robert Alston, PhD, Jillian Birch, MD, O'hara Catherine, PhD, Jeremy Whelan, MD FRCP

Blood (2013) 122 (21): 1401.

https://doi.org/10.1182/blood.V122.21.1401.1401

Published: 2013

Journal Articles

Evaluation Of IKZF1 Δ4-7 Deletion As a Suitable Marker For Minimal Residual Disease Monitoring; A Study Of 161 Consecutive Acute Lymphoblastic Leukaemia (ALL) Patients On The On-Going UKALL14 Trial

Nahid Zareian, Bella Patel, MBBS, FRCPath, Lena Rai-Shetty, PhD, Clare Rowntree, PhD, Andrew McMillan, FRCP, FRCPath, PhD, David I Marks, Tobias Menne, Paul Smith, Simon Purnell, Lynda Micklewright, Anthony V. Moorman, Adele Fielding, MB BS, PhD

Blood (2013) 122 (21): 1335.

https://doi.org/10.1182/blood.V122.21.1335.1335

Published: 2013

Journal Articles

An Optimised In Vivo Modelling System For Adult Acute Lympoblastic Leukaemia (ALL) Enables Sensitive Detection Of Leukaemia Initiating Cells (LIC) and Drug Resistant Clones

Bella Patel, MB, BS, MD FRCPath, Aditi Dey, Anna Z Castleton, MB, BS, MRCP, FRCPath, Claire Schwab, Brendan Beaton, Nahid Zareian, Christie Zhang, Anthony V Moorman, PhD, Adele Fielding

Blood (2013) 122 (21): 2641.

https://doi.org/10.1182/blood.V122.21.2641.2641

Published: 2013

Journal Articles

International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL Consortia

Blood (2011) 118 (21): 2535.

https://doi.org/10.1182/blood.V118.21.2535.2535

Published: 2011

Journal Articles

Positive Pre-Transplantation [18-F] FDG-PET Is Not a Barrier to Successful Allograft Outcomes in Chemosensitive Hodgkin Lymphoma

Karl S Peggs, Irfan Kayani, Kirsty Thomson, Emma Morris, MD, Panagiotis Kottaridis, Kirit M Ardeshna, MD, Adele Fielding, Rachael Hough, Anthony H Goldstone, MD, Ronjon Chakraverty, David C Linch, MD FMedSci, Stephen Mackinnon

Blood (2011) 118 (21): 2016.

https://doi.org/10.1182/blood.V118.21.2016.2016

Published: 2011

Journal Articles

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial

Jonathan I Sive, MBChB, Georgina Buck, Adele Fielding, MBBS, PhD, FRCPath, FRCP, Hillard M. Lazarus, MD, FACP, Mark R. Litzow, MD, Selina Luger, MD, David I. Marks, MBBS, PHD, Andrew McMillan, FRCP, FRCPath, PhD, Susan M Richards, PhD, Jacob M. Rowe, Martin S. Tallman, MD, Anthony H. Goldstone, FRCP, FRCPath

Blood (2010) 116 (21): 493.

https://doi.org/10.1182/blood.V116.21.493.493

Published: 2010

Journal Articles

Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups

Mark R. Litzow, MD, Georgina Buck, Gordon Dewald, Adele Fielding, MBBS, PhD, FRCPath, FRCP, Rhett Ketterling, Hillard M. Lazarus, MD, FACP, Selina Luger, MD, David I. Marks, MBBS, PHD, Andrew McMillan, FRCP, FRCPath, PhD, Anthony V. Moorman, PhD, Elisabeth Paietta, PhD, Susan M Richards, PhD, Jacob M. Rowe, Martin S. Tallman, MD, Anthony H. Goldstone, FRCP, FRCPath

Blood (2010) 116 (21): 524.

https://doi.org/10.1182/blood.V116.21.524.524

Published: 2010

Journal Articles

Vaccine Measles Virus Has Therapeutic Potential In B Cell Malignancy.

Bella Patel, MBBS, FRCPath, Dey Aditi, Ehsan Ghorani, Yogesh Malam, Steele Andy, R. Wickremasinghe, Rai Lena, Adele Fielding, MBBS, PhD, FRCPath, FRCP

Blood (2010) 116 (21): 3757.

https://doi.org/10.1182/blood.V116.21.3757.3757

Published: 2010

Journal Articles

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution

Blood (2010) 116 (16): 3080–3088.

https://doi.org/10.1182/blood-2010-05-286856

Published: 2010

Journal Articles

In Adults with Standard-Risk Acute Lymphoblastic Leukemia (ALL) the Greatest Benefit Is Achieved from an Allogeneic Transplant in First Complete Remission (CR) and an Autologous Transplant Is Less Effective Than Conventional Consolidation/Maintenance Chemotherapy: Final Results of the International ALL Trial (MRC UKALL XII/ECOG E2993).

Jacob M. Rowe, MD, Georgina Buck, PhD, Adele Fielding, MD, Martin S. Tallman, MD, Alan K. Burnett, MD, Raj Chopra, MD, Peter H. Wiernik, MD, Susan M. Richards, PhD, Hillard M. Lazarus, MD, Letizia Foroni, MD, Elisabeth Paietta, PhD, Mark R. Litzow, MD, David Marks, MD, Jill Durrant, MD, Anthony H. Goldstone, MD

Blood (2006) 108 (11): 2.

https://doi.org/10.1182/blood.V108.11.2.2

Published: 2006

Journal Articles

Karyotype Is an Independent Prognostic Factor in Adult Acute Lymphoblastic Leukaemia (ALL): Analysis of Cytogenetic Data from 1,235 Patients on the Medical Research Council (MRC) UKALLXII /Eastern Cooperative Oncology Group (ECOG) 2993 Trial.

Anthony V. Moorman, Christine J. Harrison, Sue M. Richards, Adele Fielding, Martin S. Tallman, Mark R. Litzow, Jacob M. Rowe, Anthony H. Goldstone, Gordon W. Dewald

Blood (2005) 106 (11): 331.

https://doi.org/10.1182/blood.V106.11.331.331

Published: 2005

Journal Articles

The Impact of Imatinib Therapy on Adult Philadelphia Positive Acute Lymphoblastic Leukaemia (ALL): Early Results from the UKALL12/ECOG 2993 Study.

Bella Patel, MBBS, BSc, Anthony H. Goldstone, MBBS, Philip Ross, BSc Pharmacology, Sue Richards, PhD, Letizia Foroni, MBBS, PhD, R. Chopra, MBBS, PhD, Adele Fielding, MBBS, PhD

Blood (2005) 106 (11): 1839.

https://doi.org/10.1182/blood.V106.11.1839.1839

Published: 2005

Journal Articles

Molecular Monitoring of Residual Disease (MRD) during Induction and Intensification Phases in Low Risk Adult B Cell ALL Treated According to the MRC UKALL12 Protocol.

Letizia Foroni, MD, PhD, Wayne Mitchell, PhD, Lena J. Rai, Anouska Casanova, Gareth Gerrard, Bella Patel, Sue Richards, Adele Fielding, Anthony H. Goldstone

Blood (2005) 106 (11): 1466.

https://doi.org/10.1182/blood.V106.11.1466.1466

Published: 2005

Journal Articles

The Value of Molecular Monitoring for Residual Disease (MRD) in Early Morphological Remitters among Adults Diagnosed with B Cell ALL and Treated According to the MRC UKALL12 Protocol.

Letizia Foroni, MD, PhD, Wayne Mitchell, PhD, Lena J. Rai, Sue Richards, Adele Fielding, Anthony H. Goldstone

Blood (2005) 106 (11): 1467.

https://doi.org/10.1182/blood.V106.11.1467.1467

Published: 2005

Journal Articles

Value of Molecular Monitoring for Minimal Residual Disease Preceding Autologous SCT Following Diagnosis of B Cell Acute Lymphoblastic Leukemia in Patients Treated with the MRC UKALL12 Protocol.

Letizia Foroni, MD, PhD, Wayne Mitchell, PhD, Lena J. Rai, Anouska Casanova, Bella Patel, MD, Sue Richards, Adele Fielding, MD, Anthony H. Goldstone

Blood (2005) 106 (11): 1468.

https://doi.org/10.1182/blood.V106.11.1468.1468

Published: 2005

NARROW

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel

Management of ALL in adults: 2024 ELN recommendations from a European expert panel

Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency

Delays in Start of Intensification Therapy Are Common for Adults with Acute Lymphoblastic Leukemia, and Are Associated with Decreased Survival in Patients Who Undergo Allogeneic Stem Cell Transplant (SCT)

Barriers To Clinical Trial Enrolment For Teenagers and Young Adults With Acute Lymphoblastic Leukaemia: The Impact of Age Eligibility Criteria

Evaluation Of IKZF1 Δ4-7 Deletion As a Suitable Marker For Minimal Residual Disease Monitoring; A Study Of 161 Consecutive Acute Lymphoblastic Leukaemia (ALL) Patients On The On-Going UKALL14 Trial

An Optimised In Vivo Modelling System For Adult Acute Lympoblastic Leukaemia (ALL) Enables Sensitive Detection Of Leukaemia Initiating Cells (LIC) and Drug Resistant Clones

International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL Consortia

Positive Pre-Transplantation [18-F] FDG-PET Is Not a Barrier to Successful Allograft Outcomes in Chemosensitive Hodgkin Lymphoma

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial

Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups

Vaccine Measles Virus Has Therapeutic Potential In B Cell Malignancy.

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution

Karyotype Is an Independent Prognostic Factor in Adult Acute Lymphoblastic Leukaemia (ALL): Analysis of Cytogenetic Data from 1,235 Patients on the Medical Research Council (MRC) UKALLXII /Eastern Cooperative Oncology Group (ECOG) 2993 Trial.

The Impact of Imatinib Therapy on Adult Philadelphia Positive Acute Lymphoblastic Leukaemia (ALL): Early Results from the UKALL12/ECOG 2993 Study.

Molecular Monitoring of Residual Disease (MRD) during Induction and Intensification Phases in Low Risk Adult B Cell ALL Treated According to the MRC UKALL12 Protocol.

The Value of Molecular Monitoring for Residual Disease (MRD) in Early Morphological Remitters among Adults Diagnosed with B Cell ALL and Treated According to the MRC UKALL12 Protocol.

Value of Molecular Monitoring for Minimal Residual Disease Preceding Autologous SCT Following Diagnosis of B Cell Acute Lymphoblastic Leukemia in Patients Treated with the MRC UKALL12 Protocol.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only